Valbenazine information

Valbenazine
Clinical data
Trade names	Ingrezza
Other names	NBI-98854
AHFS/Drugs.com	Monograph
MedlinePlus	a617023
License data	US DailyMed: Valbenazine;
Routes of; administration	By mouth
ATC code	N07XX13 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Activation by hydrolysis, deactivation by CYP3A, CYP2D6
Metabolites	[+]-α-Dihydrotetrabenazine (active metabolite)
Elimination half-life	15–22 hrs
Excretion	60% urine, 30% faeces
Identifiers
	IUPAC name (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate;
CAS Number	1025504-45-3;
PubChem CID	24795069;
DrugBank	DB11915;
ChemSpider	28536134;
UNII	54K37P50KH;
KEGG	D10675; as salt: D10999;
ChEMBL	ChEMBL2364639;
ECHA InfoCard	100.236.234
Chemical and physical data
Formula	C24H38N2O4
Molar mass	418.578 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC;
	InChI InChI=InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1; Key:GEJDGVNQKABXKG-CFKGEZKQSA-N;

Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia.^[1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.^[2]

^ ^a ^b "Ingrezza- valbenazine capsule; Ingrezza- valbenazine kit". DailyMed. 18 August 2023. Retrieved 17 November 2023.
^ O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. (October 2015). "NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study". Movement Disorders. 30 (12): 1681–7. doi:10.1002/mds.26330. PMC 5049616. PMID 26346941.

[Ingrezza_FDA_label-1] "Ingrezza- valbenazine capsule; Ingrezza- valbenazine kit". DailyMed. 18 August 2023. Retrieved 17 November 2023.

[2] O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. (October 2015). "NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study". Movement Disorders. 30 (12): 1681–7. doi:10.1002/mds.26330. PMC 5049616. PMID 26346941.

Valbenazine information

and 29 Related for: Valbenazine information

Valbenazine

Neurocrine Biosciences

Tardive dyskinesia

List of psychiatric medications

God gene

Ketamine

Bupropion

Cocaine

Typical antipsychotic

Modafinil

Chlorphenamine

Dextromethorphan

ATC code N07

Phencyclidine

Methadone

Selective serotonin reuptake inhibitor

Amitriptyline

Vortioxetine

Venlafaxine

Cyclobenzaprine

Deutetrabenazine

Pethidine

Paroxetine

Fluvoxamine

Tricyclic antidepressant

Atomoxetine

Duloxetine

Tesofensine

Escitalopram